A dual targeting drug delivery system for penetrating blood brain barrier and selectively delivering siRNA to neurons for Alzheimer's disease treatment.

CONCLUSION: In conclusion, this study preliminarily demonstrated the ApoA-I and NL4 dual modified dendrimer nanoparticles were efficient carrier for siRNA delivery to AD bearing brain. PMID: 29484985 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - Category: Biotechnology Authors: Tags: Curr Pharm Biotechnol Source Type: research

Related Links:

Abstract Galanthamine is an Amaryllidaceae-derived acetylcholinesterase inhibitor used to treat memory impairment in Alzheimer's disease and vascular dementia. There is evidence that galanthamine, in addition to its effects on acetylcholinesterase, may enhance or inhibit brain nicotinic acetylcholine receptors, which could increase or decrease the therapeutic efficacy of galanthamine, respectively. Here, we evaluated the effects of galanthamine and two others Amaryllidaceae acetylcholinesterase inhibitors (haemanthamine and tazettine) analyzed by gas chromatography – mass spectrometry and identified by comparing thei...
Source: Revista Brasileira de Farmacognosia - Category: Drugs & Pharmacology Source Type: research
TIME held its first TIME 100 Health Summit on Thursday aiming to define — and shape — the future of health care. The Summit, which is an offshoot of the magazine’s annual TIME 100 list of influential people, featured scientists, politicians and entertainers, such as former President Bill Clinton, former Vice President Al Gore, NIH Director Dr. Francis Collins, actress Selma Blair, NBA commissioner Adam Silver, comedian Tig Notaro and former Planned Parenthood President Dr. Leana Wen. The day included a range of interviews, panels and performances. Here are the biggest moments from the Summit. Former Vice ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Comedy HealthSummit19 onetime Source Type: news
Amyloid β (Aβ) in brain parenchyma is thought to play a central role in the pathogenesis of Alzheimer's disease (AD). Aβ is transported from the brain to the plasma via complex transport mechanisms at the blood-brain barrier (BBB). About 90–95% of plasma Aβ may be bound to albumin. Replacement of serum albumin in plasma has been proposed as a promising therapy for AD. However, the efficacy of this approach may be compromised by altered BBB Aβ receptors in AD, as well as multiple pools of Aβ from other organs in exchange with plasma Aβ, competing for albumin binding sites. The flow o...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
CONCLUSION: AD causes impairment of EnA and ExA. Faster reactions by AD participants to the target on the left in VT+s and more accurate reactions to the target on the left in VT-s are in agreement with reports in the literature on the lateralization of visual-spatial attention (VSA) in the right hemisphere. In this study, also in agreement with previous reports, lateralization in AD was noted in favour of the stimuli on the left in ExA. PMID: 31613976 [PubMed - in process]
Source: Turkish Journal of Psychiatry - Category: Psychiatry Authors: Tags: Turk Psikiyatri Derg Source Type: research
DISCUSSION: Aβ misfolding in blood plasma was a strong, specific risk prediction marker for clinical AD even many years before diagnosis in a community-based setting. PMID: 31611055 [PubMed - as supplied by publisher]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
Funding Opportunity RFA-AG-20-033 from the NIH Guide for Grants and Contracts. The NIA Behavioral and Social Research LEaders in Alzheimers Disease and Its Related Dementias (NIA BSR LEADR) program supports individual scientists of exceptional creativity who propose to use behavioral and social science perspectives and approaches for highly innovative, impactful, and potentially transformative theoretical, empirical, and clinical research addressing the challenges raised by Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) for individuals, their families, and society. Applications are welcome from in...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
Authors: Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN Abstract Introduction: Dementia with Lewy bodies (DLB) is an under-researched area despite being the second most common type of degenerative dementia after Alzheimer's disease. It is an area of unmet need with no approved symptomatic or disease-modifying therapies. The pharmacological management of DLB is complex and challenging because early trials of drugs for DLB have resulted in no demonstrable efficacy. Randomized controlled trials (RCTs) in the DLB population have only recently been initiated. Understanding results from previous and current clinic...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset Alzheimer disease (AD). ApoE is produced by both astrocytes and microglia in the brain, whereas hepatocytes produce the majorit...
Source: Molecular Neurodegeneration - Category: Neurology Authors: Tags: Research article Source Type: research
One of the most commonly asked questions about cognitive issues is “Is it Alzheimer’s or dementia?” The short answer is, Alzheimer’s is one type of dementia. According to the Alzheimer’s Association, “Dementia is a general term for loss of memory and other mental abilities severe enough to interfere with daily life. It is caused by physical changes in the brain.” The National Institutes of Health says that some types of dementia can be stopped or reversed with treatment. View the slideshow on HealthCentral to learn more about the different types of dementia: Carol is the Candi...
Source: Minding Our Elders - Category: Geriatrics Authors: Source Type: blogs
Source: Expert Opinion on Drug Discovery - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Alzheimer's | Biotechnology | Brain | Genetics | Nanotechnology | Neurology | Study